The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of frontline treatment regimens in follicular lymphoma: A network meta-analysis of phase III randomized controlled trials.
 
Yucai Wang
No Relationships to Disclose
 
Shouhao Zhou
No Relationships to Disclose
 
Fang Yang
No Relationships to Disclose
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Celgene (Inst); Genentech (Inst); MorphoSys (Inst)
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)
 
Thomas Matthew Habermann
No Relationships to Disclose
 
Michael Wang
Stock and Other Ownership Interests - More Health
Honoraria - Dava Oncology; Janssen Research & Development; OM Pharmaceutical Industries; Peerview
Consulting or Advisory Role - AstraZeneca; AxImmune; Bioinvent; Celgene; iOMEDICO; Janssen Research & Development; Juno Therapeutics; More Health; Pharmacyclics/Janssen; Pulse Biosciences
Research Funding - Acerta Pharma; Amgen; AstraZeneca; BeiGene; Bioinvent; Janssen Research & Development; Juno Therapeutics; Karus Therapeutics; Kite, a Gilead company; Novartis; Oncternal Therapeutics; Pharmacyclics
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Dava Oncology; Janssen Research & Development; OM Pharmaceutical Industries
 
Thomas E. Witzig
Stock and Other Ownership Interests - Valeant Pharmaceuticals International
Consulting or Advisory Role - Celgene; Seagen
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)